4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Primary Sclerosing Cholangitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 107 ongoing clinical trials involving Primary Sclerosing Cholangitis
Of the 107 trials,57 trials are in Phase II
Furthermore, 35 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Primary Sclerosing Cholangitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Primary Sclerosing Cholangitis, a gastrointestinal condition. The largest number of ongoing clinical trials for Primary Sclerosing Cholangitis is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Primary Sclerosing Cholangitis-related drug trials.

Pliant Therapeutics Inc: The leading ongoing Primary Sclerosing Cholangitis related clinical trial sponsor

Pliant Therapeutics Inc is the top sponsor for Primary Sclerosing Cholangitis-related ongoing clinical trials.

Mayo Clinic, Chemomab Therapeutics Ltd, Dr. Falk Pharma GmbH, and NGM Biopharmaceuticals Inc are among other notable clinical trial sponsors involved in Primary Sclerosing Cholangitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Primary Sclerosing Cholangitis

Ursodiol, Ursodiol and glycyrrhizin (Phosphogliv URSO), and Amylase and pepsin (Apigest) are among the key marketed drugs involving Primary Sclerosing Cholangitis.

Ursodiol was under development for the treatment of colorectal cancer, liver transplant rejection, nonalcoholic steatohepatitis, duodenal cancer. It is formulated as film coated tablets, granules and hard gelatin capsules for oral route of administration. It is a cholelitholytic agent and an epimer of chenodeoxycholic acid. Ursodiol was first approved in 1962 and is sold in New Zealand, Italy, Japan, the US, France and Canada by Teva Pharmaceutical Industries Ltd and its subsidiaries.

Amylase and pepsin (Apigest) is preparation of digestive enzymes. It is formulated as syrup for oral route of administration. Pepsin is proteolytic enzyme which hydrolyzes peptide bonds of protein. Diastase is a form of a-amylase that acts on starch (amylose and amylopectin) and breaks it down to simple sugars such as maltose and dextrins. Apigest is indicated for impaired digestion, flatulence, general digestive disturbances, dyspepsia and anorexia, loss of appetite, malnutrition and digestive supplement during pregnancy. Apigest is marketed in India by Signova Pharma Pvt Ltd.